

REP 1001 (SEQ ID NO: 1) vs HSV-1



REP 2001 (SEQ ID NO: 2) vs HSV-1



REP 3007 (SEQ ID NO: 3) vs HSV-1





FIG. 1c

, i


REP 2001 (SEQ ID NO: 2) vs HSV-1

FIG. 3a




REP 2002 vs HSV-1

FIG. 3b




REP 2003 vs HSV-1

FIG. 3c




REP 2004 vs HSV-1

FIG. 3d



REP 2016 (SEQ ID NO: 4) vs HSV-1








FIG: 8e

REP 2018 (SEQ ID NO: 6) vs HSV-1






FIG. 8f


REP 2019 (SEQ ID NO: 7) vs HSV-1



REP 2020 (SEQ ID NO: 8) vs HSV-1



REP 2121 (SEQ ID NO: 9) vs HSV-1



PAGE 20/60 * RCVD AT 8/14/2007 10:08:18 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/7 * DNIS:2733250 * CSID:514 286 5474 * DURATION (mm-ss):25-16

Rep 1001 (SEQ ID NO: 1) vs HSV-2




FIG. 12a

REP 2001 (SEQ ID NO: 2) vs HSV-2





FIG. 12b

REP 3007 (SEQ ID NO: 3) vs HSV-2



REP 2001 (SEQ ID NO: 2) vs HSV-2

FIG. 14a




FIG. 14b




FIG. 14c







FIG. 14d







REP 2036 (Vitravene; SEQ ID NO: 10) vs CMV




REP 2036 (commercial Vitravene; SEQ ID NO: 1) vs CMV





ί.



SEQUENCE COMPOSITION VS. ANTI-HSV EFFICACY




FIG: 37a

Effect of sequence composition on efficiacy against HSV-1




FIG. 37b